Phase 1 Bladder Cancer Clinical Trials
65 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 65 trials
Recruiting
Phase 1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Triple-Negative Breast CancerEsophageal CancerPancreatic Cancer+11 more
Eli Lilly and Company420 enrolled34 locationsNCT06465069
Recruiting
Phase 1Phase 2
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
Advanced Bladder Cancer
M.D. Anderson Cancer Center41 enrolled1 locationNCT06434350
Recruiting
Phase 1Phase 2
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Non Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC32 enrolled13 locationsNCT06637423
Recruiting
Phase 1Phase 2
DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
Bladder Cancer
University College, London52 enrolled7 locationsNCT04106115
Recruiting
Phase 1
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
Urothelial CancerBladder CancerGenitourinary Cancer+2 more
National Cancer Institute (NCI)100 enrolled1 locationNCT04235777
Recruiting
Phase 1
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Gastric Adenocarcinoma+10 more
IDEAYA Biosciences260 enrolled12 locationsNCT07277413
Recruiting
Phase 1Phase 2
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Breast CancerOvarian CancerProstate Cancer+6 more
University of Florida29 enrolled1 locationNCT05000294
Recruiting
Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Esophageal Squamous Cell CarcinomaCutaneous Squamous Cell CancerBladder Cancer+8 more
EvolveImmune United, Inc160 enrolled10 locationsNCT07217171
Recruiting
Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled53 locationsNCT06253871
Recruiting
Phase 1
Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
Gallbladder CancerBiliary Tract NeoplasmsCholangiocarcinoma, Intrahepatic+2 more
Shanghai Zhongshan Hospital18 enrolled1 locationNCT07614061
Recruiting
Phase 1Phase 2
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Non Muscle Invasive Bladder Cancer
SURGE Therapeutics75 enrolled20 locationsNCT05710848
Recruiting
Phase 1Phase 2
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Cervical CancerMelanomaNon-small Cell Lung Cancer+8 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting
Phase 1
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Pancreatic Ductal Adenocarcinoma (PDAC)Hepatocellular Carcinoma (HCC)Gastric Cancer (GC)+1 more
Shenzhen Xinhe Biomedical48 enrolled2 locationsNCT07594964
Recruiting
Phase 1
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
Bladder CancerUrothelial Carcinoma Bladder
Abramson Cancer Center at Penn Medicine10 enrolled1 locationNCT06586255
Recruiting
Phase 1
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Breast CancerGastric CancerOvarian Cancer+9 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 1
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Non Muscle Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center55 enrolled7 locationsNCT05126472
Recruiting
Phase 1Phase 2
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled101 locationsNCT04752722
Recruiting
Phase 1Phase 2
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Bladder Cancer
Merck Sharp & Dohme LLC55 enrolled14 locationsNCT07232602
Recruiting
Phase 1Phase 2
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Urinary Bladder NeoplasmsBladder Cancer
Merck Sharp & Dohme LLC45 enrolled14 locationsNCT07222488
Recruiting
Phase 1
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Bladder Cancer
Memorial Sloan Kettering Cancer Center20 enrolled7 locationsNCT05562791